Desager JP - Search Results

1

Lack of effect by nifedipine on hepatic mixed function oxidase in man.

Horsmans Y, Desager JP, Pauwels S, Harvengt C. Horsmans Y, et al. Among authors: desager jp. Fundam Clin Pharmacol. 1991;5(3):193-201. doi: 10.1111/j.1472-8206.1991.tb00711.x. Fundam Clin Pharmacol. 1991. PMID: 1937348

2

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Allabi AC, et al. Among authors: desager jp. Br J Clin Pharmacol. 2003 Dec;56(6):653-7. doi: 10.1046/j.1365-2125.2003.01937.x. Br J Clin Pharmacol. 2003. PMID: 14616425 Free PMC article.

3

Watercress has no Importance for the elimination of ethanol by CYP2E1 inhibition.

Desager JP, Golnez JL, De Buck C, Horsmans Y. Desager JP, et al. Pharmacol Toxicol. 2002 Sep;91(3):103-5. doi: 10.1034/j.1600-0773.2002.910302.x. Pharmacol Toxicol. 2002. PMID: 12427108 Clinical Trial.

4

Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.

Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. Chalon SA, et al. Among authors: desager jp. Clin Pharmacol Ther. 2003 Mar;73(3):178-91. doi: 10.1067/mcp.2003.25. Clin Pharmacol Ther. 2003. PMID: 12621383

5

Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.

Baririan N, Horsmans Y, Desager JP, Verbeeck R, Vanbinst R, Wallemacq P, Van Obbergh L. Baririan N, et al. Among authors: desager jp. J Clin Pharmacol. 2005 Dec;45(12):1434-41. doi: 10.1177/0091270005282629. J Clin Pharmacol. 2005. PMID: 16291719 Clinical Trial.

6

Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.

Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq P, Starkel P, Horsmans Y. Baririan N, et al. Among authors: desager jp. Clin Pharmacokinet. 2007;46(3):261-70. doi: 10.2165/00003088-200746030-00006. Clin Pharmacokinet. 2007. PMID: 17328584

7

Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation.

Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Leclercq I, et al. Among authors: desager jp. J Hepatol. 1998 Mar;28(3):410-6. doi: 10.1016/s0168-8278(98)80314-0. J Hepatol. 1998. PMID: 9551678

8

A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children.

Desager JP, Dab I, Horsmans Y, Harvengt C. Desager JP, et al. Clin Pharmacol Ther. 1993 Apr;53(4):431-5. doi: 10.1038/clpt.1993.47. Clin Pharmacol Ther. 1993. PMID: 8477559

9

Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease.

Horsmans Y, Desager JP, Hulhoven R, Harvengt C. Horsmans Y, et al. Among authors: desager jp. J Clin Pharmacol. 1993 Oct;33(10):929-32. doi: 10.1002/j.1552-4604.1993.tb01924.x. J Clin Pharmacol. 1993. PMID: 8227463

10

Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A.

Horsmans Y, Desager JP, van den Berge V, Abrassart M, Harvengt C. Horsmans Y, et al. Among authors: desager jp. Pharmacol Res. 1993 Oct-Nov;28(3):243-8. doi: 10.1006/phrs.1993.1127. Pharmacol Res. 1993. PMID: 8108314

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results